News | July 31, 2014

Data Supports Diagnostic Value of F-18 Flutemetamol in Early Onset Dementia

Study data presented at Alzheimer’s Association International Conference

July 31, 2014 — Study data presented at the Alzheimer’s Association International Conference in Copenhagen further demonstrates the diagnostic value of GE Healthcare’s investigational radiopharmaceutical product [18F]flutemetamol in confirming the presence of neuritic amyloid in those patients with early onset dementia. The data demonstrate that the use of [18F]flutemetamol increased diagnostic confidence for physicians, and in many patients, helped to confirm or exclude the diagnosis of Alzheimer’s disease and lead to changes in management.

“Early and accurate diagnoses may have implications for both prognosis and treatment among patients with early onset dementia,” said Dr. Marissa Zwan, VU University Medical Center, Amsterdam and lead investigator of the study. “Greater diagnostic confidence supports better patient management and helps physicians to determine appropriate treatment options, as well as helping patients and caregivers to plan for the future.”

Studies have shown that in early onset dementia, approximately one of three patients has an atypical clinical presentation, often making it challenging to diagnose Alzheimer’s disease, especially in its early phases. In this study, 80 patients with early onset dementia (younger than age 70), and with physician diagnostic confidence less than 90 percent, underwent [18F]flutemetamol positeon emission tomography (PET) scans, which were assessed as either amyloid positive or negative. Clinical diagnosis and diagnostic confidence was determined, both before and after disclosure of the scan results.

The data showed that 20 percent of patients had a change in diagnosis following review of the [18F]flutemetamol scan. In particular, for those patients diagnosed with Alzheimer’s disease prior to a [18F]flutemetamol scan and who had an amyloid negative result, clinical diagnosis changed in 12 of 15 patients. Overall, confidence in diagnosis significantly increased from 67(±12) percent to 90(±16) percent after disclosing PET results. Additionally, in 48 percent of patients, [18F]flutemetamol PET results led to a change in patient healthcare management (i.e. medication changes, additional care).

In October 2013, [18F]flutemetamol received approval from the U.S. Food and Drug Administration (FDA), where it is marketed as Vizamyl, for PET imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline. Vizamylis for diagnostic use only and should be used in conjunction with a clinical evaluation. Vizamyl is not licensed in any market for estimating the risk of MCI progression to clinical AD.

In June 2014, [18F]flutemetamol received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), recommending the granting of a marketing authorization for PET imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive impairment. It is not yet approved for use in Europe or Japan

“These data demonstrate the diagnostic value of [18F]flutemetamol among those with early onset dementia and add to the growing body of evidence that it can help physicians identify the histopathology associated with an Alzheimer’s disease diagnosis in specific patients,” said Ger Brophy, Ph.D., chief technology officer, GE Healthcare Life Sciences. “If and when approved in the European Union,[18F]flutemetamol will be an important tool to support assessments of patients with cognitive disorders, including AD.”

The results of this study were presented orally by Zwan and as a poster at AAIC entitled “Clinical Impact of [18F]Flutemetamol PET in Young Onset Dementia.” The study was sponsored by GE Healthcare.

For more information: newsroom.gehealthcare.com

Related Content

RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Canon Aquilion One CT Helps Gates Vascular Institute Adhere to New Stroke Guidelines
News | Computed Tomography (CT) | December 12, 2018
In stroke, time saved on imaging is time gained in the treatment window. The recently updated guidelines from the...
Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Youth Football Changes Nerve Fibers in Brain

Statistically significant clusters (red-colored) showing group differences (Control vs. Football) in white matter strain along the primary (F1) and secondary (F2) fibers. While body of corpus callosum (BBC) showed relative shrinkage in Football group, the other clusters showed relative stretching of fibers. PCR: Posterior Corona Radiata, PLIC: Posterior Limb of Internal Capsule, SCR: Superior Corona Radiata, SLF: Superior Longitudinal Fasciculus, SCC: Splenium of Corpus Callosum. Image courtesy of Kim et al.

News | Neuro Imaging | December 07, 2018
Magnetic resonance imaging (MRI) scans show repetitive blows to the head result in brain changes among youth football...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
NeuroLogica and MaxQ AI Announce Distribution Agreement
News | Stroke | November 30, 2018
Clinical diagnostics intelligence platform company MaxQ AI and Samsung NeuroLogica announced a distribution agreement...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
Vital Showcases Enterprise Imaging Advances at RSNA 2018

Global Illumination from Vital Images

News | Enterprise Imaging | November 28, 2018
Vital, a Canon Group company, will highlight the latest additions to its enterprise imaging portfolio at the 2018...